FDA, IOM holding risk-benefit assessment meeting

FDA and the Institute of Medicine will hold a public workshop on Feb. 12-13 to discuss sources of uncertainty in assessing the benefits and risks of drugs and the implications on regulatory decision-making. The workshop will cover "potential analytical and communication approaches" and their development, and incorporation into benefit/risk assessments for drugs, including during premarket review and for postmarket safety surveillance. ...